Literature DB >> 28836089

Risk factors for sodium valproate-induced renal tubular dysfunction.

Satoko Koga1, Takahisa Kimata1, Sohsaku Yamanouchi1, Shoji Tsuji1, Ken Yoshimura1, Atsushi Araki1, Kazunari Kaneko2.   

Abstract

OBJECTIVE: To explore the risk factors for the development of sodium valproate (VPA)-induced renal tubular dysfunction for early diagnosis and treatment. STUDY
DESIGN: The subjects were selected from patients who were diagnosed with epilepsy and administered VPA. Blood and spot urine samples were collected and measured the concentration of VPA, the level of serum phosphorus, serum uric acid, serum free carnitine, serum cystatin-c, and urine β2-microglobulin (BMG). Patients with urine BMG/creatinine levels above 219.2 were treated as renal proximal tubular dysfunction (RTD), with all others treated as non-RTD.
RESULTS: Eighty-seven patients, 4-48 years, 53 men and 34 women, were studied. RTD group is 17 patients and non-RTD group is 70 patients. Univariate analyses revealed that the RTD patients were more likely to be bedridden, receiving enteral tube feeding, taking more anticonvulsants, and demonstrating significantly lower serum levels of free carnitine, uric acid, and phosphorus. Among them, bedridden, free serum carnitine, and phosphorus levels were associated with the development of RTD by multivariate analysis.
CONCLUSIONS: Bedridden patients receiving VPA are susceptible to hypocarnitinemia, which can cause RTD and may lead to FS. Therefore, urinary BMG should be measured regularly in all patients receiving VPA to assess renal tubular function. An additional measurement of serum free carnitine level should be considered in patients who developed RTD. Supplementation of carnitine for those patients to prevent such complication deserves for further study.

Entities:  

Keywords:  Fanconi syndrome; Hypocarnitinemia; Renal proximal tubular dysfunction; Sodium valproate; β2-microglobulin

Mesh:

Substances:

Year:  2017        PMID: 28836089     DOI: 10.1007/s10157-017-1472-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  28 in total

1.  Fractures and Fanconi syndrome due to prolonged sodium valproate use.

Authors:  N Dhillon; W Högler
Journal:  Neuropediatrics       Date:  2011-06-29       Impact factor: 1.947

2.  Secondary renal Fanconi syndrome caused by valproate therapy.

Authors:  Toru Watanabe; Hideto Yoshikawa; Sawako Yamazaki; Yuki Abe; Tokinari Abe
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

3.  Urinary NGAL, cystatin C, β2-microglobulin, and osteopontin significance in hydronephrotic children.

Authors:  Mia Gebauer Madsen; Rikke Nørregaard; Johan Palmfeldt; Lars Henning Olsen; Jørgen Frøkiær; Troels Munch Jørgensen
Journal:  Pediatr Nephrol       Date:  2012-06-19       Impact factor: 3.714

4.  Renal toxicity induced by valproic acid (Depakene).

Authors:  E Hawkins; E Brewer
Journal:  Pediatr Pathol       Date:  1993 Nov-Dec

Review 5.  Drug-induced renal Fanconi syndrome.

Authors:  A M Hall; P Bass; R J Unwin
Journal:  QJM       Date:  2013-12-24

6.  Hypouricemia in severely disabled children II: influence of elemental enteral nutrition on the serum uric acid levels.

Authors:  Hideto Yoshikawa; Sawako Yamazaki; Tokinari Abe
Journal:  Brain Dev       Date:  2004-01       Impact factor: 1.961

7.  Fanconi syndrome caused by sodium valproate: report of three severely disabled children.

Authors:  Hideto Yoshikawa; Toru Watanabe; Tokinari Abe
Journal:  Eur J Paediatr Neurol       Date:  2002       Impact factor: 3.140

8.  Sodium-valproate-induced interstitial nephritis.

Authors:  C Y Lin; H Chiang
Journal:  Nephron       Date:  1988       Impact factor: 2.847

9.  Fanconi syndrome associated with valporic Acid: a case report.

Authors:  R Shiari; L Bagherzade; M R Alaei
Journal:  Iran Red Crescent Med J       Date:  2011-11-01       Impact factor: 0.611

Review 10.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.